Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Slides:

Advertisements

Similar presentations

Cedars Sinai Medical Center

Advertisements

Advances and Emerging Therapy for Lung Cancer

James R. Rigas Comprehensive Thoracic Oncology Program

Treatment in Advanced Non-Small Cell Lung Cancer.

CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.

Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.

S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Metastatic Spinal Cord Compression from Non-Small-Cell Lung Cancer Treated with Surgery and Adjuvant Therapies by Yu Tang, Jintao Qu, Juan Wu, Song Li,

Dr Purvish M Parikh MD, DNB, FICP, PhD, ECMO, CPI, MBA 12 th July 2014, Kolkata 17th ICRO PG Teaching Course.

NSCLC stage IIIA type of chemotherapy ? Swiss tumor board Bern – Dr. Christian Monnerat Département Pluridisciplaire d’Oncologie – Hôpital Neuchâtelois.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Joan Schiller, MD Professor of Medicine Chief, Division of Hematology/Oncology University of Texas Southwestern Medical Center Deputy Director Simmons.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis.

Volume 18, Issue 6, Pages (September 2015)

Treatment of Stage I and II Non-small Cell Lung Cancer

Perioperative Complications after Neoadjuvant Chemoradiation for Locally-Advanced Esophageal Cancer: A Comparison of Platinum/5-FU and Carboplatin/Paclitaxel.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

CHEMO-IMMUNO-TARGET THERAPIES

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

The Nurse View: Management of Pancreatic Cancer

Prognosis of younger patients in non-small cell lung cancer

Jabbour E et al. Proc ASH 2015;Abstract 83.

Adjuvant chemotherapy in NSCLC

Table 1 Baseline patient characteristics

Intervista a Angelo Delmonte

Patient Case 1 Patient Case 1: PET/CT Scan.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Treatment Algorithms in Melanoma: Past, Present, and Future

Highlights From the Inaugural COPD7USA Conference: Focus on Treatment Challenges in COPD.

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Treatment of Stage I and II Non-small Cell Lung Cancer

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

EVALUTE THE EFFICACY OF ADJUVANT REGIMEN 3FEC- 3T IN STAGE II BREAST CANCER Hai Phong, 2017 LÊ THU HÀ, Ph.D. Nguyễn Khánh Hà, Dr.

MJ O’Connell for the ACCENT Collaborative Group

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

Background: Gene Expression

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Practical Guidance on the Management of Pan-Negative NSCLC

Treatment of Stage I and II Non-small Cell Lung Cancer

What’s new in stage III lung cancer?

Challenges in LA SCCHN.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.

Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada Christopher M. Booth,

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Using Q-learning Method in Identify Optimal Treatment Regime

Treatment of Stage III Non-small Cell Lung Cancer

Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Presentation transcript:

Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Case 1: Introduction

Case 1: Imaging and Laboratory Results

Case 1: Imaging and Laboratory Results

Organ Function and Age

Decline in Lung Function With Age and Smoking

Surgical Management and Outcomes in Older Patients with Early-Stage NSCLC

Improved Outcomes With Higher Surgery Rates for Older Patients With NSCLC

Case 1: Surgical Evaluation

Case 1: Surgical Evaluation

CALGB 9633

JBR.10 Trial: Overall Survival

Survival by Age: Meta-Analysis

Overall Survival by Age Group in the Postadoption Cohort 2004-2006*

Postoperative Adjuvant Chemotherapy in Older Patients

Adjuvant Therapy: Cisplatin vs Carboplatin

Case 1: Treatment

Case 2: Patient Introduction

Case 2: Patient Introduction

TREAT Study Design

TREAT Study Results

Interim Analysis of ECOG 1505: Chemotherapy Administered

Interim Analysis of ECOG 1505: Toxicity

Case 2: Treatment

Thank you for participating in this activity.